New heart scan could speed up amyloidosis diagnosis

NCT ID NCT07605741

Not yet recruiting Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a faster type of bone scan (CZT-SPECT) can accurately diagnose transthyretin cardiac amyloidosis, a serious heart condition. Researchers will compare the new scan with the standard method in 200 patients. If it works, it could make diagnosis quicker and easier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bone scintigraphy (CZT-SPECT and conventional camera)
What this could lead to: If successful, this could make diagnosing cardiac amyloidosis faster and more reliable, potentially improving patient care.
What could go wrong: This is an early-stage diagnostic study, not a treatment trial. The new scan may not match the accuracy of current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC AMYLOIDOSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.